Literature DB >> 18003796

Candida nivariensis isolated from an Indonesian human immunodeficiency virus-infected patient suffering from oropharyngeal candidiasis.

Retno Wahyuningsih1, Ivo N SahBandar, Bart Theelen, Ferry Hagen, Gé Poot, Jacques F Meis, Anna Rozalyani, Ridhawati Sjam, Djoko Widodo, Samsuridjal Djauzi, Teun Boekhout.   

Abstract

Candida nivariensis was isolated from an Indonesian human immunodeficiency virus-infected patient who suffered from oropharyngeal candidiasis and was identified with molecular tools. Our isolate demonstrated low MICs to amphotericin B, flucytosine, posaconazole, caspofungin, and isavuconazole and was susceptible to fluconazole, itraconazole, and voriconazole.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18003796      PMCID： PMC2224287          DOI： 10.1128/JCM.01660-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus.

Authors:  Julia Alcoba-Flórez; Sebastián Méndez-Alvarez; Josep Cano; Josep Guarro; Eduardo Pérez-Roth; María del Pilar Arévalo
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Catheter-related fungemia due to fluconazole-resistant Candida nivariensis.

Authors:  Shin-ichi Fujita; Yasuko Senda; Tikako Okusi; Yumi Ota; Hideaki Takada; Kazunori Yamada; Mitsuhiro Kawano
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

3.  Use of amplified fragment length polymorphism analysis to identify medically important Candida spp., including C. dubliniensis.

Authors:  A Borst; B Theelen; E Reinders; T Boekhout; A C Fluit; P H M Savelkoul
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Oral lesions in infection with human immunodeficiency virus.

Authors:  Maeve M Coogan; John Greenspan; Stephen J Challacombe
Journal:  Bull World Health Organ       Date:  2005-09-30       Impact factor: 9.408

5.  PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast.

Authors:  Julia Alcoba-Flórez; María del Pilar Arévalo; F Javier González-Paredes; Josep Cano; Josep Guarro; Eduardo Pérez-Roth; Sebastián Méndez-Alvarez
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

6.  Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata.

Authors:  Alexandra Correia; Paula Sampaio; Steve James; Célia Pais
Journal:  Int J Syst Evol Microbiol       Date:  2006-01       Impact factor: 2.747

7.  Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population.

Authors:  Inés María Bravo; María Correnti; Laura Escalona; Marianella Perrone; Aubert Brito; Vilma Tovar; Helen Rivera
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2006-01-01

8.  Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar.

Authors:  Ikechukwu Okoli; Christie A Oyeka; Kyung J Kwon-Chung; Bart Theelen; Vincent Robert; Johannes Z Groenewald; Diane C McFadden; Arturo Casadevall; Teun Boekhout
Journal:  FEMS Yeast Res       Date:  2006-09-27       Impact factor: 2.796

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948
View more
  14 in total

Review 1.  Candida nivariensis as a New Emergent Agent of Vulvovaginal Candidiasis: Description of Cases and Review of Published Studies.

Authors:  Pilar Aznar-Marin; Fátima Galan-Sanchez; Pilar Marin-Casanova; Pedro García-Martos; Manuel Rodríguez-Iglesias
Journal:  Mycopathologia       Date:  2015-12-26       Impact factor: 2.574

2.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

3.  Occurrence and characterization of Candida nivariensis from a culture collection of Candida glabrata clinical isolates in Malaysia.

Authors:  Sun Tee Tay; Azadeh Lotfalikhani; Negar Shafiei Sabet; Sasheela Ponnampalavanar; Sofiah Sulaiman; Shiang Ling Na; Kee Peng Ng
Journal:  Mycopathologia       Date:  2014-07-15       Impact factor: 2.574

4.  Rapid discrimination between Candida glabrata, Candida nivariensis, and Candida bracarensis by use of a singleplex PCR.

Authors:  A Enache-Angoulvant; J Guitard; F Grenouillet; T Martin; P Durrens; C Fairhead; C Hennequin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

5.  Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis.

Authors:  Jianling Li; Yingying Shan; Shangrong Fan; Xiaoping Liu
Journal:  Mycopathologia       Date:  2014-08-15       Impact factor: 2.574

6.  Differentiation of Candida glabrata, C. nivariensis and C. bracarensis based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA.

Authors:  H Mirhendi; B Bruun; H C Schønheyder; J J Christensen; K Fuursted; B Gahrn-Hansen; H K Johansen; L Nielsen; J D Knudsen; M C Arendrup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-24       Impact factor: 3.267

7.  Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: First description of Candida nivariensis in Argentina.

Authors:  Soraya Eugenia Morales-López; Constanza G Taverna; María Eugenia Bosco-Borgeat; Ivana Maldonado; Walter Vivot; Wanda Szusz; Guillermo Garcia-Effron; Susana B Córdoba
Journal:  Mycopathologia       Date:  2016-09-28       Impact factor: 2.574

8.  First report of Candida bracarensis in Mexico: hydrolytic enzymes and antifungal susceptibility pattern.

Authors:  Rogelio de J Treviño-Rangel; José F Espinosa-Pérez; Hiram Villanueva-Lozano; Alexandra M Montoya; Angel Andrade; Alexandro Bonifaz; Gloria M González
Journal:  Folia Microbiol (Praha)       Date:  2018-02-27       Impact factor: 2.099

9.  Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael Gherna; Justin A Bishop; William G Merz; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

10.  New clonal strain of Candida auris, Delhi, India.

Authors:  Anuradha Chowdhary; Cheshta Sharma; Shalini Duggal; Kshitij Agarwal; Anupam Prakash; Pradeep Kumar Singh; Sarika Jain; Shallu Kathuria; Harbans S Randhawa; Ferry Hagen; Jacques F Meis
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.